Annual Congress: Hematologic Malignancies
Register now for the NCCN 2022 Annual Congress: Hematologic Malignancies™ to access high-quality educational content, networking opportunities, and more!
Dates: Friday, October 14, 2022 – Saturday, October 15, 2022
Location: New York Marriott Marquis | New York, New York
Attendance options: Attend either in-person in New York or remotely through a virtual event platform. All attendees will have full access to:
- All live and on-demand sessions
- An opportunity to engage in interactive Q&A sessions with speakers
- The NCCN Exhibition Hall
Join us in New York!
Those attending in-person will have additional networking opportunities, including a Welcome Reception on Friday evening. Those attending onsite will also receive complimentary breakfast, lunch, and refreshments during breaks.
Continuing Education
This 1.5-day, CE-certified event will focus on the latest advances in hematologic malignancies. Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, the program will feature panel discussions with world-renowned experts, interactive presentations, and challenging patient cases that highlight recent updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies for patients with hematologic malignancies.
This year’s agenda includes 18 on-demand and live educational sessions designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies. This program is approved for AMA PRA Category 1 Credit™ and ABIM, ABPath, and ABMS MOC for physicians and is also certified for credit for nurses, pharmacists, and other oncology professionals.
Agenda topics include:
|
|
For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.
- AstraZeneca
- GlaxoSmithKline
- Lilly
- Novartis
- Seagen
- Incyte
- Merck & Co., Inc.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
This activity is supported by educational funding provided by Amgen.
This activity is supported by a medical education grant from Karyopharm Therapeutics.
Exhibition Hall
Visit the NCCN Exhibition Hall in-person and virtually for networking opportunities and to gather the latest information from industry-sponsored exhibits, the Patient Advocacy Pavilion, and more.
For exhibitor opportunities, contact Jennifer Tredwell, Vice President, Marketing and Communications
Related Program
NCCN 2022 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™
Saturday, October 15, 2022
New York, New York
Registration is separate from the NCCN Hematologic Malignancies Congress. Virtual attendance option available.
Topics Include:
- Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia
- Debate – Response Milestones that Matter in Chronic Myeloid Leukemia: MMR vs. CCyR
- Patient Case Studies and Panel Discussion: Leukemias
- Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management
- Recommendations for Managing Adults with Histiocytic Neoplasms: New NCCN Guidelines
- Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?
- Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
- Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
- Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Minimal Residual Disease Assessment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Is it Ready for Routine Clinical Practice?
- Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
- Patient Case Studies and Panel Discussion: Lymphomas
- Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease
- Optimizing First-Line Therapy for Advanced Stage Classic Hodgkin Lymphoma
Accreditation
This program is approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals.
Supporters
- AstraZeneca
- Daiichi Sankyo
- Gilead Sciences, Inc. and Kite, A Gilead Company
- GlaxoSmithKline
- Novartis
- Pfizer Inc.
- Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Seagen Inc. (formerly Seattle Genetics, Inc.)
Takeda
This activity is supported by independent medical education grants from:
- ADC Therapeutics
- Bristol Myers Squibb
- MorphoSys
Pharmacyclics LLC and Janssen and Jazz Pharmaceuticals
Related Programs
Recorded Presentations from the NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ are now available.
Gold Level Sponsors
BeiGeneIncyte
Janssen Oncology
Silver Level Sponsors
AstraZenecaOncopeptides
Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.
Bronze Level Sponsors
AbbVie Astellas
Jazz Pharmaceuticals
Karyopharm Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc
Save the dates!
NCCN 2023 Annual Congress: Hematologic Malignancies™Hilton San Francisco Union Square • San Francisco, California
Friday, September 22, 2023 – Saturday, September 23, 2023